-
According to a new survey of clinicians who treat teen girls with pelvic inflammatory disease (PID), national guidance designed to inform decisions about hospitalization versus outpatient care has lead to provider uncertainty in choosing the most effective treatment approach.
-
Women with breast cancer susceptibility gene (BRCA) mutations are at risk for breast and ovarian cancers. Ovarian cancer often escapes early detection because laboratory and imaging screening tools are less effective than those developed for breast cancer. Ovarian cancer is marked with a less-robust five-year survival rate (44%), compared with nearly 90% for breast cancer.
-
In a prospective cohort of obese, reproductive-aged women, there were no changes in the number of ovulatory cycles, but there was a shortening of the follicular phase and an improvement in sexual function after gastric bypass surgery.
-
OB/GYN Clinical Alert editorial board transitions.
-
Overt maternal hypothyroidism and hyperthyroidism each complicate about 3/1000 pregnancies. However, subclinical hypothyroidism can accompany as many as 2.5% of pregnancies. Both problems require careful surveillance because of the potential to cause significant maternal and fetal complications.
-
-
Although users of depot medroxyprogesterone acetate (DMPA) experienced more bone fractures than users of other contraceptives, their risk of bone fractures was higher at baseline before initiating DMPA and did not change while on DMPA. This suggests that confounding, unknown factors led to the association between DMPA and fractures in previous studies.
-
In a large, multicenter, randomized study of women in Europe who presented with ectopic pregnancy, there was no significant difference in the rate of subsequent intrauterine pregnancy observed following early ectopic pregnancy managed with medical therapy or conservative (salpingostomy) surgery, or following acute ectopic pregnancy managed with radical (salpingectomy) or conservative surgery.
-
-
The contraceptive vaginal ring (NuvaRing, Merck & Co., Whitehouse Station, NJ) and patch (Ortho Evra, Ortho Womens Health & Urology, Raritan, NJ). are two effective options for women who choose combined hormonal methods.
